Sunridge Corporate Update

FOUNTAIN HILLS, Ariz., April 21, 2011 /PRNewswire/ -- Sunridge International (OTCBB/OTCQB: SNDZ), holds the patent on a vacuum fixation device and suction rings for the treatment of open angle and pigmentary glaucoma worldwide. President and CEO, G. Richard Smith is announcing an update on a number of current developments with the company:

• Current distribution agreements
• Expansion of distribution agreements
• Company owned and operated clinics

Mr. Smith announced that, "We recently signed a new exclusive distributor in Turkey.  We are negotiating additional agreements at the present time for additional territories, and have received notice of large pending orders for equipment from our current distributors.

"A Study for reimbursement approval is beginning in the Middle East under the direction of our exclusive distributor in that region.  Once approved, this will allow patients to receive our PNT treatment at no out of pocket cost to them.  This should provide a major revenue source to Sunridge, in the form of equipment sales."

Mr. Smith went on to say, "Our business plan is moving forward as anticipated. As previously announced, the company recently decided to move forward with company owned and operated glaucoma treatment centers, and we are actively moving forward with the funding of our first clinic.  We hope to have the funding completed within the next 30-60 days."

Mr. Smith was recently interviewed by CEOCast.com regarding the company, the company's proprietary device and procedure, and recent events. That interview can be accessed on the internet by going to www.ceocast.com

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.

Forward Looking Statements

This press release and the statements of representatives of Sunridge International, Inc. (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information.  These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "ultimately" or similar expressions.  All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect.  Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the Securities and Exchange Commission (http://www.sec.gov).  All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors.  The Company undertakes no duty to update these forward-looking statements except as required by law.

CONTACT:
Jeff Smith, Sunridge International
T:  +1-480-837-6165
e-mail: [email protected]

MEDIA:
Victor Webb, Marston Webb International
T: (212) 684-6601
e-mail: [email protected]

SOURCE Sunridge International